61 – 70 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
2010) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23. p.251-259(
- Contribution to journal › Article
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
(
- Contribution to journal › Article
- 2009
-
Mark
Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Is the prognostic value of Ki-67 dependent on ER status and histological grade?
(
- Contribution to journal › Published meeting abstract
-
Mark
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor
(
- Contribution to journal › Article
- 2008
-
Mark
Different routine histopathology after frozen section of sentinel nodes in breast cancer
2008) 6th Biennial International Sentinel Node Society Meeting In Annals of Surgical Oncology 15(Suppl. 1). p.37-38(
- Contribution to journal › Published meeting abstract
-
Mark
The CD44(+)/CD24(-) phenotype is enriched in basal-like breast tumors
(
- Contribution to journal › Article
-
Mark
Epidermal Growth Factor Receptor (EGFR) in primary breast cancer-protein expression, but not gene copy number, gives important prognostic information in tamoxifen treated patients
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.187-187(
- Contribution to journal › Published meeting abstract
-
Mark
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
(
- Contribution to journal › Article
-
Mark
Breast cancer patients with micrometastases only: Is a basis provided for tailored treatment?
(
- Contribution to journal › Article